Gabapentin Capsule
Product Images NDC 71335-2279

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2279). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing a formula to calculate creatinine clearance (CLCr) based on age in years, weight in kilograms, and serum creatinine in mg/dL, including a multiplication factor of 0.85 for female patients.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin showing a cyclohexane ring bonded to a side chain with amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain scores over an 8-week period during a clinical study. The x-axis represents weeks from baseline to 8, and the y-axis represents mean pain scores from 0 to 10. Two data sets are shown: placebo (open circles) with relatively stable pain scores, and Gabapentin 3600 mg/day (solid triangles) with a decreasing pain score trend. The graph is divided into a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph depicting mean pain scores over a 7-week period comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score values from 0 to 10.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) dosages in two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600 mg; Study 2 shows 14% responders for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated by p-values below 0.01 and 0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart illustrating percentage difference versus daily dose (mg) from three studies labeled a, b, and c. The x-axis shows daily doses from 600 to 1800 mg, and the y-axis represents the percentage difference from 2% to 22%. Data points are distinguished by different shading for each study.*

FDA Label Image

Label (Lbl713352279)

Label for Gabapentin Capsules USP, 100 mg, manufactured by ACI Healthcare Limited and repackaged by Bryant Ranch Prepack, Inc. The label indicates a package size of 1000 capsules, with storage instructions and a child-resistant closure requirement. The NDC is 71335-2279-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.